Insider · CIK 0001341382

Topper James N

CIK 0001341382 Name as filed on the most recent filing

Filed as Topper James N (75)

968 transaction lines · from 75 filings · filed 2005-12-14 to 2025-09-30 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

953 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-09-26 P, Open-market purchase MBX Biosciences, Inc.MBX 11,999,988, acquired Open Form 4 filing 0001231919-25-000267
2025-09-15 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 15,639, acquired Open Form 4 filing 0001341382-25-000007
2025-09-08 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 31,487, acquired Open Form 4 filing 0001415889-25-024111
2025-08-11 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 11,294, acquired Open Form 4 filing 0001415889-25-021660
2025-06-25 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 23,012, acquired Open Form 4 filing 0001415889-25-018316
2025-06-24 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 46,454, acquired Open Form 4 filing 0001415889-25-018316
2025-06-16 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 167,381, acquired Open Form 4 filing 0001415889-25-017693
2025-05-21 P, Open-market purchase Phathom Pharmaceuticals, Inc.PHAT 14,609, acquired Open Form 4 filing 0001415889-25-014428
2025-05-14 P, Open-market purchase Phathom Pharmaceuticals, Inc.PHAT 20,919, acquired Open Form 4 filing 0001415889-25-013134
2025-05-13 P, Open-market purchase Phathom Pharmaceuticals, Inc.PHAT 3,543, acquired Open Form 4 filing 0001415889-25-013134
2025-05-12 P, Open-market purchase Phathom Pharmaceuticals, Inc.PHAT 38,301, acquired Open Form 4 filing 0001415889-25-012770
2025-05-09 P, Open-market purchase Phathom Pharmaceuticals, Inc.PHAT 2 lines 114,616, acquired Open Form 4 filing 0001415889-25-012770
2025-03-26 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 25,521, acquired Open Form 4 filing 0001415889-25-009198
2025-03-04 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 84,203, acquired Open Form 4 filing 0001415889-25-007263
2024-09-16 P, Open-market purchase MBX Biosciences, Inc.MBX 10,000,000, acquired Open Form 4 filing 0000950170-24-107536
2024-04-25 S, Open-market sale Alpine Immune Sciences, Inc.ALPN 1,227, disposed Open Form 4 filing 0001415889-24-011664
2024-04-04 P, Open-market purchase HilleVax, Inc.HLVX 128,325, acquired Open Form 4 filing 0001415889-24-010490
2024-03-26 P, Open-market purchase NewAmsterdam Pharma Co N.V.NAMS 181,224, acquired Open Form 4 filing 0001415889-24-009330
2023-10-24 P, Open-market purchase Arcutis Biotherapeutics, Inc.ARQT 200,000, acquired Open Form 4 filing 0001209191-23-053662
2022-08-05 P, Open-market purchase Arcutis Biotherapeutics, Inc.ARQT 5,000,000, acquired Open Form 4 filing 0001209191-22-045014
2022-05-03 P, Open-market purchase HilleVax, Inc.HLVX 30,000,002, acquired Open Form 4 filing 0000899243-22-016310
2022-02-11 P, Open-market purchase Alpine Immune Sciences, Inc.ALPN 799,989, acquired Open Form 4 filing 0001209191-22-009821
2020-12-11 P, Open-market purchase Frazier Lifesciences Acquisition CorpFLAC 10,000,000, acquired Open Form 4 filing 0001104659-20-134761
2020-10-20 P, Open-market purchase Tarsus Pharmaceuticals, Inc.TARS 5,000,000, acquired Open Form 4 filing 0001209191-20-055425
2020-03-03 P, Open-market purchase Passage BIO, Inc.PASG 9,900,000, acquired Open Form 4 filing 0001209191-20-015666
2020-02-04 P, Open-market purchase Arcutis Biotherapeutics, Inc.ARQT 8,500,000, acquired Open Form 4 filing 0001209191-20-007100
2020-01-09 S, Open-market sale Entasis Therapeutics Holdings Inc.ETTX 250,010, disposed Open Form 4 filing 0001209191-20-003162
2019-10-29 P, Open-market purchase Phathom Pharmaceuticals, Inc.PHAT 19,999,989, acquired Open Form 4 filing 0001209191-19-054525
2019-07-22 P, Open-market purchase Mirum Pharmaceuticals, Inc.MIRM 6,750,000, acquired Open Form 4 filing 0001209191-19-043024
2019-01-18 P, Open-market purchase Alpine Immune Sciences, Inc.ALPN 1,999,997, acquired Open Form 4 filing 0001209191-19-004779
2018-09-28 P, Open-market purchase Entasis Therapeutics Holdings Inc.ETTX 5,638,305, acquired Open Form 4 filing 0001209191-18-053540
2018-06-25 P, Open-market purchase Aptinyx Inc.APTX 2,400,000, acquired Open Form 4 filing 0001104659-18-042310
2017-11-06 P, Open-market purchase Allena Pharmaceuticals, Inc.ALNA 7,000,000, acquired Open Form 4 filing 0000899243-17-025455
2017-02-14 P, Open-market purchase Sierra Oncology, Inc.SRRA 8,000,000, acquired Open Form 4 filing 0001209191-17-011565
2017-01-31 P, Open-market purchase Anaptysbio IncANAB 2 lines 6,000,000, acquired Open Form 4 filing 0001209191-17-006406
2015-07-21 P, Open-market purchase ProNAi Therapeutics IncDNAI 3,740,000, acquired Open Form 4 filing 0001209191-15-061938
2015-05-12 P, Open-market purchase Collegium Pharmaceutical, IncCOLL 1,800,000, acquired Open Form 4 filing 0001192482-15-000206
2009-02-26 S, Open-market sale LA Jolla Pharmaceutical CoLJPC 154,927, disposed Open Form 4 filing 0001209191-09-011948
2009-02-25 S, Open-market sale LA Jolla Pharmaceutical CoLJPC 92,038, disposed Open Form 4 filing 0001209191-09-011948
2009-02-24 S, Open-market sale LA Jolla Pharmaceutical CoLJPC 120,827, disposed Open Form 4 filing 0001209191-09-011948
2008-03-10 P, Open-market purchase Amicus Therapeutics IncFOLD 5 lines 7,651, acquired Open Form 4 filing 0001144204-08-014371
2008-03-10 P, Open-market purchase Amicus Therapeutics IncFOLD 14,322, acquired Open Form 4 filing 0001144204-08-014372
2008-03-10 P, Open-market purchase Amicus Therapeutics IncFOLD 14,280, acquired Open Form 4 filing 0001144204-08-014372
2008-03-10 P, Open-market purchase Amicus Therapeutics IncFOLD 3,864, acquired Open Form 4 filing 0001144204-08-014372

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 949
  • Open-market sale 4
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Topper James N, insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001341382

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.